ࡱ> %('&n~ZBW,e6VxPNG  IHDRVƒgAMA pHYsNIDATxI㸒E{LjZOSIQKW(Eb{w'3CKFӷ_Efsbw'~ '~baa݊~czmwCC&1em}e1lzJcwsAw'Ƅx&˥Fi4Ms\1bR<}n5nucL\axi崟Qw)X|'l8=*/0 ub WX4zuߘnڿ/2.ld\y c?QJa&"bu=SkcL,?ߑ%X:@u#1$?G@1m_a's8t>_ڿ#C`iu(?ߑE6K)}Ƭ`E#QT~h^cV$ AA'Ь{}-򦫽@b:]-XOi^l mۮN`~\6לQ]V"~\ TU{a}''8;z1&l/8$`̤m[#b[nc7 <`7]GkgYXhN1#b~Yfx{i.ð]/nQvU~8{ۚӶ~8>i^PDu7}"ΐ?JlYXE~b++ ~O`7+pkVyGl;F.}"!3/7 3c_L~#M81ز_-~qEhA~N>u<ٝ9cXpCY$I$I4IǩRCXeoӸ.Tt@i0 jt~ml8ɲl<-/[M4%yҞ`\|$M3>$AY]/!J$I旍=!I,w ǻҢ3Xd^UU9"W{{pHD^MW^-biǒ(ԢƘiI41^`:ev^YY:˲wE-xKTo%PrTM棔2c$#~Nv7Jsedcc⢪WL_)#^{$I7jyߥH9m[d?/qAbR&ضDJ#mNd _(}C/nߊu]ۚx|W6 ȜʜOKJ~ElK?8e @VU['S7o1џ&nU`_=DN~/c\~^!~YlqYd2km _Zs1u_9~9}cֱH/'n5%K}weqtQ *EQĒ=5͡zE%]w/~:%?V¿LEq>8,L=f+ 8Ƶ0 Ze0 u]zNgyGJ,ˎ1qI|̝$9ʸb"Gd1 嬫/ y}}-}11l[xE?sinXKCPaǴ_)n.,Z(rK|@|zNPCd>B\ c| |s0C,n ~TYbY0dcO5rE8+428fu拾 h_ԥIOq@?Zӽ$o̠+l~st@y޴m;? ,~5l._{S;b33И>vUU|ә?Yˉ35_jNFƸ/ Kp nWS䠐kd7g}Xv远h&Op4r#oИmgZaeL?[9>Eeց}??J,nj ˢ~?'Z(M2E/NY?4Mߩ֘U:`67,/V#{{ThZ/ݸ+elcr Vů_ n(q8@_)&b^___g9d_o)Tۏ8}|>zl1]׭EQy^ULGeUHQsFy/%wm?N_&rND""#|4Ǘ>[Qt2x-R䃒fl]#熗[1?5/Q(L_<{iDtrLP0GazQ0G\jO|SFYE98cp@/Kӌ*^/#|b++{[)Ca/iH&؉ ves,,K/cdN'VI@߭؄LH89,#)r?_)%堯//[d(pҖuD}t:~"2ÚeP,R> $AևzT?exR _ɖW+ɲ,k}M}ݎ(zJ$WگRHp>O ii)0)knZ#GB_0UJGdRuK2V+(캶m[_As\1uh骒p7Kc6J\(݃nA2"D " I|[?odѥ(V-Y)3#C(kd/oT\(!ci{gߑɁpR7ܯ9oi%a$Iʲ y|&(ّqB\wqܷbx젗fEQ8Ҏ넯<^{Y7$] ZxA.[9x/>Y bwd;@/W'Lu4m,: !f>UKY af9w+BDnEy:?=Yqu13ލ&fF_O-ſ-t Ӟ(2~re4՟1`gvx坥 O$<<:>Iᡭ 1{w߯u +{3IXƻӶRLBo~=V~헻<6`.ﺎ[a"{O#*t~9}dw!L{Vܒk~ wk\Kߋc2l1=j75߃w{?!MxO{i#2#U_Y:~V=bfL/`EO4j`%ۋHu$YݿNř9\cgl20t]'PPAt^F0'+ƟoүO!/ r 1eZi&Iu[ b;v7n1R?Zqsb㿋ْl:GT[z$ a$V%'ڦ ۏ]b|ⴶih?\1^j EQĞR݊eopeyٶ/M|]fuE@.˝i~;{;~i߭@e2㩯hRJ ݆ȍT_RKU<˲#/.|ƽcQA?n5Ku;}sDֱ_$ p{]`;`'<]+4^@!~QOt:9 o.'}-y-{k&p\\ٟ$ɢ>v`9w3<`l| KcYAb, Y9[=ϑ3@"qeL'w7?'߶QiP-𻩽e\Yni 4uSI?B;µEp2~g'1Ƿ?e?daxxYyfrp]+Z맾{m;{;/7/ZE~_iOAS~/iˣgs)2?>^bgo} kI./eug_aw:o;w4 iYwy<:iiO Ghe‹qOMW_5iuax$׿Ta1˲$IR_̿ Iu5,MS=9֒~Y4[hJȲ\NxG3Xf'RU-PNG  IHDRÒ}gAMA pHYsN IDATxg|U-jB *,,"*Wյ(תW@WQtE"` .-B !nn{~9<3g1(Bx/@!$1 mĀBiBѦI !D&1 mĀBf)LCb@!~F_Ij֓H !U8ѡ4z!Тp/faf<ˉ$_wTd7ߩ$BuMe,81k-f9 1 (NN]WSTu O,Gq|$B5[Ei!)?KQŸ)=Y. 1 Udc+u-{^էcq?nU%sz$Bî55&mAS;/9'<=77!P4=s<դη>P_Jb@!T+?PYy?B2W6T41ĀBVHU|: ~H !:K~#uᅚ{3VtPs*H !:N+ƫmyD$KiV5!Pij26Τ2Om_EU#(Nݪ&1 88T,Ncyp9^@i: UBu8U ?:E .lW$B[XK\Eb@!.As84ciPsH !JFИYzcwZIc$B?C Zh-\A$u$B?f5nVVC#$Qq{^%w6l1`an')Hu_haֽG!z{~ z($z(!ݼE0/w]'֎)ex3!DkC̵d|Cugsf;b'/{C1hדDpb2/Q2($hbw-qXe{`Ar4,`0VMr;1xԡ/?\.!-2v)s`.v%sCG秒DyכVgw}{/NABR]fK\NP r o?c^9!r:ݯax}C5UW~oĤ H !Z+@qRIy&'g}]fX0oT"<6~:ʳ\p;1 Z7{K ȠIy۟w|X>*؁ unhnk?urܥĀ4W{Ӱ6=,Z.ta=LY"v!2.jҌ?Ѥajh!ŠBvaĀK#aډ(!qƻ ڝ.6˸PXOK$x}ԇZ!DkƀվLVVҮc+9!5/ ,vB6 Uf )7l Č'i;g6!Dce߽`"}7Uq֋3ǥlߎSqEÇnWB6)z7ah P}~o^3 b(f՟(_)%8U?1`VCh6TYb@fG1չJ,2=a-0i'S1 "Ō`p7 м;ro{f!Da43t;52*ϗIh|'rM"]s w0șF:8+ff$mXVMϮvHN@׶]wU;qCSVfR[B6otCQZ~Sg2F 7ol֓+^Y[to^gkiĀ1>Nlu.i`'>Q殀~jAr݊}6l_ݔ Bi@b؛wk3;W)>bFq 9ݴu^{_ƍ AhGBّ)K !ڤ |Z>PC:WE@XАN,'mk۟ɩڝ`=(ޗubø5 :vuY}h{لRfo,C^s62q„?QCsFP}ȡEbbuHQY_p8[un.%4 hOu8gгxp~tHqP]Á`NW0s`޵hl2ǿgtB ~^ތPYB:G< 2ٟ.)7%̪_߁nW{IK !Z {%ȡ" K!R6յF3&|B T;9,s G> s]w,@b@2T&gǿ&g}51ANU5[mVc3/Bǿb3;*qh#9 'M\8ȭ]\& !ZK/Eha4a|N xuϫBgG.1vMg# hUʇ,+ \֗>Gb@rkkV !q\ =&vB66 cuJ2g-A 6tn@Ѣt7452B100yɜNp/UU(`:)wᚕA;3ctf9/\s i(ͩp/QuZ[++ty9 ed /½eb>"?R>O 4F?麶qv*1@.֧S!DT|=qr% s:ϯਦ$(9BU"lʱa+^ӊӎ`h`'v%? ͛dN6'} B"8&Np:]/ZŎӁDQjO &3kya&/')}xtȻLM]B/ ֶmv0w?ynÍٴow&93 tl1Ԙ𘆫L!!D?I;(&+Nʳ$`;T7%yio n|k< !Z3;"'Wh:pxWzN4,Vn܉OL3hCko9YĀMb&ik3;2ץu8F:lcͱ|P\DGh-!Dk8Y`vt4Jj,K]tw@n[޿s%WuKH[[5&@׉J |Cu.ict߹= 7BvN+9IXhn' u$r"9!w;\7wo& 4HM$m 'W yTik[pM$@@;"&o'pNzkҽt^ ?5)QG BR@~*99y 831A*[8Uoۣ@By5ڻ݀]O &o>l~)9-l2+Hu OB%g=KN!VݺBTO_KH\S֌yzC/8C MYhZ6mfNnM|QorP;јcI1Q !Z$Me՜\<k8iNo};?m.Ā5W^%ږB̾(vOU**Niv={z`UMBVZ7%MpzDžRYx)3w}H !ZX1uI +=_[M# ;XѺ8,~=s rcAeE뚲zĴӦ\1IĀ)`]nh` .EPŽX;dxC@!QHo.¿Mo֓lMܚXȤ3ٞ{z޶C^R*{γY=f׿}-Ƥa!?|Ko޿E B.(fm$@`p -[fv|\![&4pYBRvQ``R÷JKkSMe̫docBU=iCI]I7O;ε'7 xc@ mA%ˠ iIH[Ek1 hv`+qf6`Cn P Y~ (J X5N)oLl  bE5k;ߋi9w b^IMyFЀ LWPb(rP@2#T@@咝Bxb)e8^X#ask1cB IVQ+GC&EPq=/ie̠(OMsGYƘ e+5Zo%Tp{4XB`TƼFIE)%aIBP !\r9;"m(9uw,Vފ $^\( {R>*OJxÒ?sV3.lqβ18 eA P 6r5 L@ 0N8a,f nu$$$}TaWڼ6N[u(V_U^ >͋ h>l80(X1m y흳e6)$$$}B˭5βf}34B+\-)$$$}tXo~rT^G12)$$$}f# :Ajd*~b_EGvh2@BB'ĭD>tE M>qT )_ !cA@O174By`vVOԄ %*TEA(t+RTa* Øt&Δ+2IgjWP) 5݊n$(V6U0bCm].:%RAFE4v4 eB Ba36>ACwJKK+*D!S6t[(S ݌>Q,w B0e5It>CufV_)mv P)TOGO3RnaY%F| tiȪR*۱($ ByZCB ZSm,SMk .X|hڝ{[6(-;{;os 6<6' YUĦkRAw 'H&:v0*5 Oބ񗑚-W\.&dn#w1w&.Ӎ—7_kZCys]β?T@,N!0.6=cVm`w[yUsUdqͧ2O%d%DL={w?V?q~%n(QeW]lc*j|iFz(>|0%zJdp}=H.tm Ť/AD}˩_Jֶ6q[CG淪{v/dXx|C"|0;Ob<"֨Bңk%턞<&!6=vT#S"x4@a1cjг1NZY&~{ӀwF-l牾+B<Mq]q؁5gHsw3~qA<qqbnUUQudJپ}bմt9*+(KcFNzSOxgD/ fSA\G0#nx]:S;xm;s(z":\7u~? H+Y$EdӀC]ڹR _/-V|/אQK?ogMκ:؁jG1Fޙ3t0p Aј1voO3x7M.e 9rn ltɍQX^N^3}gRJRDrQ~K\& *Tu80J+k(#PjU㳸{o=ilҟerw OkZҸIO$'4 N@Am7٧ׇok+#G%jRl6Lٰ2hTMAm~׭'qt?VwgՙU &,n77M e%o/- +b{`<#NӁIgd"wy󦍜0(m܎0dg?-ڐVi52Ьk״ VA^ESlaꆈ{ eNʳgWٖY5yD9h5@R3-ծv5cG/^9v0g@*XZ%;::rbhYCՐY O4 ۥ;.$ň  'mXϱkC׆ uf9@=,m_꾮7vkWR+5@A(> 'p&&nHM"ۯ״֬sS*-4 AjwTpɀ`n;`S joҨW ZMҤJ饂c<â>,XXKYzS) Q\k0Q0F\o{ I%h%K5FA Em~C# 3眙ٝ=s5c͉5d _WE?Pb q|hI7MU iʦjᘟ=>xfcf8*qZ!C\!"2a7w8_ԫ.͍:/5ԂoҨw9ཷ.Z5] ~q b#~ۘ:< :װܐW#9pBdINGo}~既_4ƈ, W9qhƊ;8;25)iho'DdQml]P ֶ1^zGQ>{/Lz-Uhg΀ W/WiTtmL ćp{ȅK n6nT-W1o؇被QխdF31ƒzwWs0aO-{O?:}5Ըb̊=& at΋,)oVxs6> 05`*nқAC2 P{=y6 әu݆^J995789m{Ɨ-R[-f:xJ`9 3]z4Ο2;x!ed> #k_jZvyvY~ A7HeBqFPM9Y["py7k/ٻ"_LH|︓'E|RO3006=T4!IS*|4T=HE(VpUQedRK̚0 sPW4]~sXJX߱#ZD`L{H!F|~ Y#3rbf]v@y"xH;K-F1c䚘5TZ;`fC=9$GA p0J=-.} uo;$-n@\|`>σBN'AE7&|-x\ݿ&*fpA"Njoa,ԑGȢ>+ᄧ^@o%V%SQJJN9 ݤ?m1p4n;^%K(~xta9ACCqWMF}æPg9!sm +IҭWk`FPl6n& >1%` )h-$25,5/l,䡓,4<-ؘ0Q}T=D7O>- fu(;4L٪hUkF0ܟjSyxc{:U@9|~4͂Xoա3t0KJNeggg;UI^eY f1MMkImYv̆m!K$A ㄸj*- og"EQX%)v'D3PAQPR})>FZA0$L\A Db@TellFzdRӬ PiU(v_<~J؜gNHr@(c;T&%S=}:zyp\BkpC{JⳈ|1;S"]z#ѓ)ŻR|𲸾IhZ]F+o|N=D} lP..D1x 0@U%bc-d-9[9S(-g9לׯUUUY(z>CXbspr6nD̠4oİEQQ J>ńvu4*zPa_w[wWkW.u(QT+?{NE}ǀ={0y;\ܑ8F7nJ[UMHSgPb| 0v~}fblROw>Fei,׬a";X{PV3E*[*^[L2 L?~0c5 nxdnjc:IISZATPS@7Ro:5 'K'@drگi̪}Nt6,?< .ͫܝ6.5d:q^.ŬDS1=`>K~$J},Ca1A fYc١ ALE$=]_ԿNSumuGibfq-`J^X7 f@܄ dAAf5MTT[Ue2?UνT:C#n^EglO$hl>{6ng# 8Z:S*m%[ѫGc* !+ـVo%OQxCZVuŇL\~d9(:aD?ҚJZDʢڢ򣩳˟Wͯn%mHst/N<8aī#^4վ:2bZt'h`fgЇ= ڮrY_j˟#G{GJVl6 ZT+SȊuٻwubpVM7;x6(㿋_ Ph3olֹs=U_5nձc̈́9~ ;AUƎƺ:ݚ=9D)cSh= u e3ohYtd&67d.GE?,mS%E'QJ*5:MJN&J> xuq)-ʫ#+ 1@M9 z۶Mp\[mKiQ\%(L[]b`V-꾺V6Et1k1(xPo'Ѡ(1O4oܐ`%Fy Ur.Tv&I^x}#F+5U?}ң+՚5kNPGȦ)5]WO>,Τ>c)dr6.uNjvy6@C[(C??Sr kk%p(*Ԋڢ򜇯6\*6C>b?nAؔ 3T6W^~vyoj6eެS pn뎉t+)38&Ph/"ڪWͯ({ (# .y޴.uWUK{1+22K9Z$E'>ьkvd鑸qݧ4:|ĵGzb3{9o7!rZYS4ʳ+W]acхk aY$,)*iÙ rϝ;o3d>CلI'%ecjyxKu%ӄe2mo sj)u (X]Aæ7,Y^37+^ u eWU-c=|'9axT|cD:$T(*5J~,rPhՄ4)d%%5̰+ƬH %mxUV})6O52 DlX8Sδa Ӫt"h5Kf*Ofv}Vui71-!V=~~S.N;6AI\!+fp kRqS,7WOWe0n b qzb:Y09Z$_xϿ܁ǟEDۡ0^3<6O;ՎV70Y!(‚Y'AV^rF^F4Äeb+uv=/s}fگi0,,Pܠ{:Bq(~8Y ,w3ytrYYϤ@6-HF H5j:j-irA H pd3;UUm՚~f  㧧D0дgB/R!9X,@:%7~Лp"KAXylRxB٭iu{a8< [1?,?Ԙ!I$ ZOJrb00 f\+`0j`5X `0̸ `5`00 f\k`0q V 3j`5X `0̸ `5`00 f\k`0q=yyP$aqZF:ɇ p;X,IBP{/um}mzd7ã꿊7nR?oPj3f|Sͳev}X~EEq[o̵[u[uQEQiciu$f x}Vn{PcEÍ cIi =HfrbTu: hfޖ^/ z~LH̨qy\mI&6=1l"ͭ۷_<yze^K=O`RԤ>:Marl`5Z{[{-PEc)'[o!9=2 ^dz._:pWL^QI8xN4G":m2U'X `Ɔ:mr*S^KB'l6Ӕi/yApȊ+={o4IDATHWO:Mrzd:3 L[`5!9U+gF2a,Um+|\뾆򓓞X!7n _ h6 U( WVjcXdFt_$l\С.6g;uʳ'~r:}t{I"[N`st+8Ws<$!<Ⱦ<\ )ӤB:zu\ 3sN^[eEWi7['1~w1@k:(+ 7rqN*{<I$IrULU0rH 63c_^!<$)<ǖf,8{=Pnn$VM[3׽^Yes<}IUL$yn;9"yo9YJn-2T+&8|lWO7s{݋/HYYkoXln\ V޳{+`>cW]h9jv|ZP\I<(m,YG۝;X|aЅC0>N֟|wlwهR^tP4S|QŖ[F-dyS'LZB S6hIH ,d Qp`f u?çGuQMF&*$~dFҝP/KϬd|.< dzm=pwtK?N"Aګ|2-f; Kw)UмGl<џn9lʹl%GCQ3TooBD`ߠ^r{<Ǽ<\>u^QWGPC 2T]uρ}f +8Ìx<5*H#TBӧQ=XuWZzrxoïzoi50?,D$UA9)<)HXyKބxkokQe?93`( H`-X?Ӽl2xl{ԕgN Ory\eMe|Np 7m0(eJd|68^{j\헡Ҝ{)bɋ.s笟~Z4wMwm5v7+coQ~ouZ@ o$ Vq92~=hJ Of6g-q,x'HbH̞8C3LᙛgW̴mFM9 9(}襣W| `Z'BeujU8Bd.dEe>VX@zqQwE$u1jnӎy*Ho_^rt ,xe3w:LHK >\_ice[ђ>,6so7#ϼRTz&(mzu 1!1JF\] 23'̤effCAgSÇ KJl{O;J6|^9?߽;H@\^Kou[5g%bfVT쭳P4nUVUTÒJ:BTwQgu-Tۿ^Tes-67LTڐ`{vtT6jJD R*vKީۆv 99g=q6/=26;.)mmH3vurdbuzԈraz<#~ƢEұǐ==Mm6fhJv꡸um_&GOf6/ ;.CxE%<0tV\Q|sSrz#A( iQ/uw~Eۏpɮӻ=s ;~eL0#y+QМ9Tsӕ+w,shC m'dfŇ# s7P\QQEEH8w#mNͻ솇QQ!Рm%FC ,|fI!U0J MFM7 x8)jID8wy]4/2-vZzd:3h/tw0艡/,Fju}zZ ~[;_Wo qЋ9/RS%?`fk LρT(M K!%ei_g0i؆Х$ZKxmZ/T4W|w;={Ew3qiШ|kP(m7)} Tjʛo:}V2/x{Vf`wi6Y vH#~IhM3XoC LTp?0y7{^Kfo%|4]?^*r\f UUFdtBDD- u7c6%oj헑bm(`snn\6tȌM{hL058VG VQEkvtCY!U0_8Q(#2KwQDGmszԽx>1,`^#hBX!$X>]zNȌ }0*J4lI3M{O)3Qܳ|? @_ETP4>N)-T"z?`5U?]zmePTe/lvIߔ«ٱf}`3 you9=Nw4u(gѫÄ"X^>l$q|"JXP²qFdBaZq.!^}UZԸwx%o:Wg#jp*sa)U|گQpRDj]^䷄yIj\y ? z5*PТ'</:$b?򄡒P(C'--İDj!#䧱8,}>$w8XXc Sz&U~pžiE){8>j3 50CB$!bًMaACvnJʩ+Z''1 Vgk=lUEn f6CraqZ6#*W@}n \8 VÉW:K_{D3M --ł\]vAIK6!dI|HbըIkL\5$B4F]7%A *i+ v.pǤ3fy&Lۙ?K8/{ ayeEIWHkkݙۇ Ћb1Xs~16`VkᵫϮBsQwKxZ\_O CPJimv7 Q'ל+v ˮ4* \|tq?E+==*MgZ=BH778jlu׺ALIz[V+ 5ݙ2WZӬ <- OL>*çqʢg,xO^uCeta:kjdg+~@^po$cyJIMßsga:sg!dқi_x^^z H[oQnCa Yvx9[$,hWV_r-߶==~OƮ]3g\H<2ᙸZ3W1doM]qt7FX_V/F'lۈߍV;Gp 3O.:qeU!Y7߃[ڪ:~HfGklq S}j 3ccqmx^ku9``n.6ߗ~Nm)S}Lz'=F6yvY,ʩnYpBl?3,s/*1̾$Ù("q>GGǗLodwKM{R],} EQ~l ?dZ y=9F'.*DT۲)*:uTWӑs^-z|ϣ(B5OJ͡Ȕz!j}dXIlcX۴)A*VG)a)Ԡ{p<$w/<i b8{(<|k^ۡe2Q܌\&ۆ BΆb kA/hplq+xP4giSz&kEDxuA9d5@>>,Pe RH<_k,צ~llįTUȯwgg9H.U Dbita|O4]Z®/Ɉ###GKU-ݕf:>%%9׊k;eFژo/)mx7*TjY?'!a@ v46@ ;aGC@ hH  (75SIENDB`(    "PowerPoint.Show.80BMicrosoft PowerPoint Presentation/ 00DArialgs4(0(:A 0 DTimes New Roman(0(:A 0  DWingdingsRoman(0(:A 0 0DSymbolgsRoman(0(:A 0  B0.  @n?" dd@  @@`` T9    /Xb$ZBW,e6Vxb$h$>RU-U# lAA1?@8ʚ;ʚ;g44d4d@:A 0ppp@ <4ddddl$ 04 <4BdBdl # 0A9___PPT10 6?  O  =5.PBM Participation in the Medicare Drug Benefit//$The National Medicare Prescription Drug Conference February 27, 2004 Terry S. Latanich Government Affairs Consultant Medco Health Solutions 4PFFPotential Roles for PBMs $ 2004 Discount Card Sponsor drug discount card plans Provide  Intel-side for M+C discount cards 2006 Funded Benefit (Direct Participation) Serve as PDPs Serve as PDPs with dialed-down risk Serve as federal fall-back plansPN+SN+S Potential Roles for PBMs $ 2006 Funded Benefit (Indirect participation) Provide PBM services to traditional risk bearing organizations, e.g., insurers, health plans which choose to become: PDPs Regional PPOs Support employer-sponsored plans B"  !Key Capabilities Provided by PBMs"" Develop pharmacy networks Implement POS technology and DUR programs for seniors Track patterns of prescribing by physicians and patterns of usage by seniors to improve care Facilitate e-prescribing to improve patient care and outcomes !Key Capabilities Provided by PBMs"" Specific obligations under HR 1 Develop medication therapy management programs Long sought by pharmacy Source of reimbursement has been hurdle Negotiate rebates and price concessions with drug manufacturers XOP@PAPPO@ADiscount Card Program 3Only deliverable prior to 2004 elections New business opportunity for PBMs which have historically been focused on selling to health plans, not in the direct to consumer market Financial Investment Required Cost of initial enrollment versus ongoing operations Build brand identification before 2006 benefit NS/S/ Discount Card ^CMS regulations recognize that $30 enrollment fee will not cover the costs of enrollment and ongoing operations Expectation has been created that manufacturers will participate in funding savings, not just pharmacy Manufacturers must offer significant discounts and rebates to make the card successful Controlling Drug Prices Price versus utilization as cost-driver Formulary categories delegated to USP Medical Necessity Overrides Plans can establish objective criteria for approval Must be specific to a beneficiary, not physician preference E-prescribing as formulary tool LjZpZ"ZZjp# PBMs role in 2006 Benefit QRisk is mitigated in the early years, but still remains high PBMs have not assumed insurance risk No reliable utilization history in early years PBMs have an after-tax profit of 1-2% per SEC filings PBMs will review current business model How many PDPs emerge in early years Will PDPs enter if dialed down risk or fall-back implemented BcPPc  !PBMs as Fall-Back Administrators "  ?Cannot be a PDP or subcontractor in any plan nationwide and still seek fall-back provider status May not establish brand identity Not a traditional role for PBMs Support current clients or move closer to an fiscal intermediary model Government role in developing formularies and negotiating prices in the fall-back plan  Conclusions   BFirst litmus test for success will be the discount card program; early indications are high level of interest Whether M+C, new regional PPOs, employer-based programs become widespread offerors or free-standing PDPs or reduced risk PDPs become the most prevalent offerings, PBMs will be key to the success of the program 2AA  ` ̙33` ` ff3333f` 333MMM` f` f` 3>?" d_@r?nFrd(@%u  ZrlPF n?" dd@   @@``PT!    `(p>>  -K0  <V(  <P < C A"2 < # lxaxa? 1?"o>f  X Click to edit Master title style!!  @ < Zxaxa1 ?"oN   FClick to edit Master text styles Second Level Third Level Fourth Level!   G   < <1?"~ *40( 2     rB < <D1?"ggP < C A"B6h < Z䟞xaxa1 ?"`?U 0    < <1?"/ _ F 2003 Medco Health Solutions, Inc.8$0 "B  < R ?1? Base"pp  B < s *޽h ? 333MMM80___PPT10.=@9l chelseapier -K0 @(  @P @ C A"2 @ Z@Jxaxa1 ?"hr  X Click to edit Master title style!!    @ ZxLxaxa1 ?"haU   [#Click to edit Master subtitle style$$  rB @ <D1?"ggP @ C A"'6M @ <P1?"/ _ F 2003 Medco Health Solutions, Inc.8$0 "BB @ s *޽h ? 333MMM80___PPT10.=@9l 0 ,*(  , , 0B P    X*  , 0K     Z* d , c $ ?   , 0lN  0  RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S , 6x3 _P   X*  , 6P _   Z* H , 0޽h ? 3380___PPT10.Q$-K0  $(  r  S U@.  r  S V@0P  H  0޽h ? 33___PPT10i. +D=' = @B + -K0 0 0(   x  c $4<o>f   x  c $$<o   H  0޽h ? 33___PPT10i.PA+D=' = @B + -K0 0P<(  P~ P s *@<o>f   ~ P s *<o   H P 0޽h ? 33___PPT10i.PA+D=' = @B + -K0 H<(  H~ H s *(<o>f   ~ H s *<o   H H 0޽h ? 33___PPT10i.PA+D=' = @B + -K0 @T<(  T~ T s *ȍ<o>f   ~ T s *<o   H T 0޽h ? 33___PPT10i.PA+D=' = @B + -K0 @<(  ~  s *̞<o>f   ~  s *T͞<`?   H  0޽h ? 33___PPT10i.PA+D=' = @B + -K0 `<(  ~  s *dԞ<o>f   ~  s *$՞<-   H  0޽h ? 33___PPT10i.PA+D=' = @B + -K0 p<(  ~  s *ڞ<o>f   ~  s *۞<`?   H  0޽h ? 33___PPT10i.PA+D=' = @B + -K0 $<(  $~ $ s *<o>f   ~ $ s *t<   H $ 0޽h ? 33___PPT10i.PA+D=' = @B + -K0 (<(  (~ ( s *l<o>f   ~ ( s *< `o-   H ( 0޽h ? 33___PPT10i.PA+D=' = @B + -K0  L<(  L~ L s *4<`/x   ~ L s *|5< `o-   H L 0޽h ? 33___PPT10i.PA+D=' = @B +\x} n͆EX@۝vA(!fHd#όz_NS6{ۑ Ɯ>, c`L)[@t2# lƢ?*6 h$LEHp2pM}w`n}a@m9|ZZ%~GPGm_7s=j;XI|$pp$ H 8$m R&qyO$H@SM$h: y@ p4YfRFeC9H u@p^hŀt6b1 @2 @,d h +@րlY1+" {@9Z@N6h3 g@.\"r @^f\9΃9<Y˹6EG>6菆?zL #🏿y7wC@? ]s0us.:B~ "R ^jVD7g'=n8S<[JT k7pM @p`Q WflV9vWO^%OD~̈́ﻲX!#yh$\\_⺈\|?bf.v?p1 oA g,H`8"V^N|mېh*Hƭpax*ރ_Sn'pOAh[>Cy$7͎Cᬉ5<ցDpDCu6Ǖ⍊C$zӈx_Z[+@(d$:H 2*gB$I~訷~uО7hٝB6_߄%1J&][*şgjA;-#: V}P;2oo8THCd7Pp:c.[V3pn>$2GQ4M 乆[iD.xi$2Ύ#1Zo 6Ύ49"p`8Xrzkn[Op|uQ`fN!!o2yIg3<{-u rEyR=w@@km™MlC&l3a6#r=)Tj3PL"x@I{y(>uT5TZ.є#$}x *嫵0_5ppɵA8±WgAԊpb,EpԎ9Rpo}W4IFŘB%Ǎj1Śs'SL5P[@;ik"x V$Bl)D-DCs}x=:_1*G>`զA<~VppẢpc8q <#/yőWъ0fOqR(}I*t|An;LXh3$'taD0wǡk>hy?r@ ?a /g>Z0W39 *_9q`FY=tѺՑ!6кw!^8zΊÖ6 ng83J=0|FK8yQ08NS|> xu^r3\B~׎'R۶7J= |W.= sЇ Y[GzDY{=k 8owEzz? gLTm;FN򛺞i%GfQ9)ԅc&fBDHЦnx-.E  "#xMr[ID'hSF#$kAC4+5B{%8UQ@zA>c'qu6CsOb==qC+ޑuoF_a / Ĕ3xGzuFXn l ;:wx0 FEzb;j4vIi;jەCT\<ب&ȸ["&\gnB39mxH2FxPJ-)ق?;D]䊐Ee.ʋ1Dj9HLYׅkyϨ=#I|tٓ8\k?rF| ;AZێ??V(c0iK%mmD*ˉT:d/ZUa:@TͬUKhDWPTh$47'aMCsQQQ(41P[tU ǽ,^ɎvXA0kt"s)cs&d[:-@WI 8ƙ4Cе=(ZOO3h"Q8r*6︊Mh4-P~Ԩf`1v9&3?e(֗H 87Ƀl?T訹|xIx@:/G 6jU=Ȣk)t*uN%|\TAO< "IyEDWp .iuhn0Z^?t Б7l8K3#r̸rڜ+./8:C4)h|< JW"Y2u8~ 0de[H+Ì}\5X= dG<ѩO/G.6VI'VO@gphq q Gќx4WQBAC3*j=ܷ4hED)ȍ-oU xg\h.C{}P_1C0vJ[rEHFۇ7RrV?h-X^őw6( G{KVlTf IC|p H ={jϝ]rl +mf!OWni&(\-xٟOCeFt9PB(pg;\PˎU+Ṡ) F^Nt9C/0A`€\ )ࡀϱ_k+ʙy㬉ht3j 0/&I W? Ǚ!T* Ecqԇp'jN ȴ`28@6d<b$F sps[x0u% *1"ȷ,[t43LbJ01Y 1!?o-rdK6F%~@!0œC@itW% o߀Rar# 29^4yiV@C/:фhl5jv7i>\L\ s b894:83MjTC\')Pɨ%'O, ~5X h&b9 d p?ΤNN3VA9 7!; ytёJ$@'*pVLw:~~mb슇D3AЀŃbW8ƨD ݔcNLБr@a|`Z 8@͈r.BGBxbT%@5 يqN9Z:WNMَ#؍`Y7V[# 49澗ƹU~.GHNNX=W3Z'9$66vr6YjrF h}=D~ZC9CN"?}drV|)ѭ*8O[Qs"#OFF7A f{nˣ?pAƸrg! dcX\csnW \hPgXI(`9KX 0yA߰#_nF7E| 7lAvG:&6Dc` aqw+;v9wj; -3T@ñ*߸IcuxƮ%m>[,8q\$qEdX `Mr8"+'m3IR!3,3o *Px> waOa}p)灛Cp8j@0u.|w%p#*3E% ߩc8|\ۈЖs16<م\Fu8zX!М>o 1^dc<6H(J==`JcI'JA#>MI   Oy| dDI-*r@QqBBPCF4g 4$Z i`7۪|kAQG8}?qG d(`$QGST?O51mkW!p"#Wger~)dlzTSwпVH6OH8pP,Q _lqF|xjxsfX2$jFQ ȂYրd{{{Չ/D|utl06tl1룞>c,Q /Fk5â(FpԶ[7/Abõ}"\['-gЗ188Gs+ȝ w֐E#8[cBQD4HRi p+q@5 } 5v/^1pi.y?,.#X^N{9nhЅC?ǻd[\0ϏDŽX97 DF>PDiVBM?I8rm\%dP2qr%#ɔPx1]@&NbȃApy#!^L@~Eo?+W0şM]f8=N_  }ƍfdOk moP;U,N4΢qڹpgt, GPu{"_?q D:^I:8~$AvAɇ|6'6Ɔ4Nb&gs]-hn$<,Gr/DVIqoI=*ĘF~p '.N$cI0"~$q88^&4 Exjq_RY"T? T=Pm"P/@9T8rjgj ! c@=j心^`ًzC/@+1?bg߂G /{b~hƃ/'\,!!·y_O@++w@^o#%hx6?6MRT0hZ h~}H3(7'8y-+}4k P. 6;, ].3BbZ`Ei';9dP94%$G,$ 6Ibt}=>ݵ7~ʎs̛#Ye%2%s5>/RAwrx([_IvzӉ 5vfvExml "^y/;{F]«KzVv5;:z=jl%k+އ]sH33SVۈy/sisd]Ϧ.W'gkTAFf,\rkqdjOfY:%ΰ] 2P*9#C/F\Mjןfvug"7{ %gZ_|qQ՛x1o{WrO1Zr˕g߾OsvOPK:J]| 03]{OȲC a,tfױKXW{vKXBo5 n;5|{YJM]a5FN|I>]?ݾ2D>~ʼ]/׫m1Я-V[4R5ÕގJB\̛ yPc;;u)7R=y1^0]+@쪪[}}r#/3vN٫xP[=Uqi#E7/FRdVTό[hUSY#&7R'3zi%=i~R6QPq_,%(%K/F}UI}6D)> Y%ϼ1eQ xhccBj\*(mXmv#Ylv %ޟy<243'?sJZ6%#@Kêl93+7ݺ[dq0ļw1Wג_ec:3 %S9pG,qRzTnqO:VO,yIA5j=0L4ײy*isc*\fBaơv?^t-/xv,dY~;2foJ@4!/_M]E+0)&+6 﨎zs sVgE},y<.zʏ X5s+hUj77Ek. y?+TxvLNEɀ[-%! t[%))ռQ7QЧͰDw حƮkfG&u-d̳̺>nOZq_Uʗjt5d7_߶.E}*'*n\Rijb^GX 6z.鈽 )MW5'&3]8G+Z`uH^acǫƖ!қe+^}~SnZ^G}8 @U#^6=ۙ1M],3IA1 4֞ռ"<ΰtגwff̍x,W2k{5}gI #ݓu.^"D`BU9}@K)&yY^rӭ~KsVߏjy2%sI'g:n7+:q@M4HV52\wpU֥I:{[TZ>/GN`NInx["IoG:˾?_avk; ;VDV^P-;9?VQJImk_wq }Djr;$!KS5sGDO쎗92Ԟ(}c63qä 郤xB!S[v6܎a _7|RFwuGQ|[v~_'w&N|;zy#kV'=)^K[۶-58P#A(6TlyT̐T;ӮSoq{6L`ؼ =Zg>o0pN;;jFdB 6 vnH=]y;.S<<biЃ\5}C 2xԝJ꟝:][;ى)W Y:oodGICwe g S{dy [,/1eHضam Wze{G(LʗgPyu&aӳy>O7$TeV}3q]z,]lhx&jV&ѓe)i!}#E*L봙m֎ZsF[`tARՉ^{..[zRAwӂm=5qE]-Δ:ow,!}HsSVnj|$r72gX> ɿt0zyN}nqpF̖ qK˿: ;,MlMZE7ltJ^fy#g Grj|nJR*a9a'/y]Ѯl'|w<_0לcӷԱP3SK7O0J;is\e5/+#;ec׮hXNܶ7r늶uщy/V<LV].6v~Q{W ^ߚ1ӈˏ, 9]h|}7#=AcvU9b#^e0\$&.7x43^3mX[>I/]ǛsHCw4ʢ,g}ͺt$SY*Vz'[(w3Qc)5L3(Fa+r~}Plz)^OVʏbտ n1m 7SIi^=P+z>D:K%m;*R:&DY-M|G>/:]1:N7%A[1V !ifvȰHl|;ISi+egetԽ35ZY廱7?i8ljok \z -iYo_|UWؾzDxܻrXi3I&te!GdlȖzy&3zGy냜N1kJ7]s+OBqNLGaUR?jqg'ـ컯]LnZ#YALvwBeo1IV_^7ex"gb̤5_d=|L^Kw~Jdn0{wZv}V蹎MOlcXձU1sH;jǒ"Dfg-Qt/̹0^ּ{noq˕~]Z\]N/a8}RT9ѳ~Qm"+{oS~eU_*,~Y13=K̥^^voгXaW;?H!vGZ=)?\ؒŕLط68Ku{';H>6=QC =(347nhK"dH>9Z7S\'8ޝifue^帕)sUbz}'gt`D}>26j YjE$+Oh=ϢJz$<(ÿtդwBRlR" Τ-mzbm3OL8~Gs8(+P_5)w")貶E]ykXWM7-`c> (LX{ufh݉#!E.|7;g0lfkm vP\JuW܁P\0^٘#`:AJ(~$dbWMAw{X5Fnlu~M, L+ZYE3 ;?wOeD\_ĕ@IfuT.(rY'^G)96IX?8B7%q#[fۮ~lmd6/Ϛ<$LSEܥn5^Pq5K^lDmBOyyߩ#CCKnf>$vKN˺2Z #> F;畝LvUMEJݚY[Y&&(WG^#y 747o3ӟלk8HN% < c9^RRQmUtV;}H,RV }g!1QHMb-{?JjYfe熽 fs[=`9@^v5&k.M]=i߅Cwi {,3n.&YUsKס!aߠݛ"\ѿl 4i6|UW5M~\gbjKTp*ˑ"mI5YlFo_$1n62աiӺ銾3ߪ}Wc(MطƩk,w)ɠ'%QڥVqP$cWUfȰc 'P;}Gos3ykqD9`q3CR5MywFVa5KHj=nm ٟ.QN8Oz,\@!@_{E׈=;&zP^\ӈV@2;R40Z)ᑡ[.qm9ƖS}F6;VEPC#> ƆCyIo2w/}Iن3gH@0Na4e" Ѳɧ;=m*{PU 1\UՃ,"Ubq@hv 8Sɠ`Vv `V.x'R-|TxZ)ӱ4%d[2^DA~և6V=ǰŵ HF&ܳV6i;fYΝ_Z۳,vq./cc,ZM[rQ4**q;NddԯHyBm+Y돸ה+>hhN]?$4M3Qm1 "RĮ #˯Jlu4ңuf Pi-[u9֔)4fR՗/[>:Wt@WȹeQ{,ffOK*o3gHa{P_櫅L]pA~~܅DGQ? C8 ;GJ{+>?i N`Xa3e]vzۑ[qm]j/$gծI+h$OwG >yցݶrDm*wI{-[HP%M\O0 kXi"Nvc}\¾w6u\dZbKU9>jgk >.,Wcw͎תFx+]bm}Ȧ mkdr6+~ؑreiIf8;EƝ3ms -w/iΒ6GuUa]oWل=]:hlrg/\dZ} {UK˦.^^rf -չKmſ^hsڱn^[GG_zLٝYpfNu*=*3O|g_۹#CX8UA)ːt'o5?֞ϖV1sz^쮒>;^V͊ކK7,W M'7z.::e7}]ii0W=YKE)353@mALP+ى̫_ T+\Oidv2uY ߧvkmkFS *uh5FsQ8R$uYWh+^j;,p O>>q0# 8VFuAIMi\{NZ壍ֶ"v6PJ ],/HEOkՐ -d tCFD>FĩɔEu*LmaV;(hc=Ă?v6}'}'z08k'i{|F߲X}]B/6Xe)09R"`b Io:{pc=һ͕Y+J'gyƐM=V`x{7DGשi`/?Ty :oΝk?'0g/'NH'aDEf}igx,XlckMk(gl\&*{e97Y~.*Yٔ;&ܾ4w+13{zXZcmvæYiaNOZsi{U1&``8gGC޿rҁEѻNP.Yy1w?N'Zꓦ6mxqslOŗ*ȵ};>ŭ%*%ի]]`c^yUS7\xi%a+_ fL^%̕تuI<_am]Ņ W?_{#C}0a]")_8"4H7Z~[r`c/'M]3%KVOkMhXUtd`vkx+q9&o_<+b{,8{Ѝ-*u&JJf-qo`cqоP.vyJ$s;Gh3C'V|# MUj -0H G-|S>kHPި߯t>O e rœ/;c$OknNEܗ1;yéV36eMB(`>Vw>C:m2>%pt2<ɂpYR`T:31+2yOXUm*伀I{Akr_鄚\'14 B%&V*(ٯ"-Q=osǂ'̫$RkOYWd=4]DW'(/]>38{dKԆbO bDV=5µ8sR[v4\=4{)LιpPH cw3XoSwnȎ mK3}Som3]"X*Ob?.(eԉ%*qtזw awOS|{IQC*E[)^.o5Ԗ->hMqr\:fK., ws:crJgP5/S7RΪVl-jZ}/p14d$F3fOG#w/8U@HVշY̓q /6;:Ϯ&7|=;tv6%wRcg'BkC~ygEB67u4a 0( } )NkWmzų3j،՟vdM dyFDXHqyѠY ,<<3cbޚErrk$DR;]4KӪEi*g$BrlF|6\KBgwvmp6>GjROY*g3-v=gש)z8gRL009ůKiߊMO~?ᵆ[kW+rdٯa_PXRbDa}?a{ӛ8 1}ѭZc2^tn{۹bpTвK1|D/c7cfhKORU{(Xt:^ꞗ)n/d[،&-&\ɣw\j}Sϟ#Sn8r]I i<<(6Hj~gl3*.z̋?n\=DHzi{{fvnFFvr$p'|5.op7CE@]Dx-q՗Kg$D^tK{O4ܳ`7X[[}iTPu>YZ>v_:+Grgԁg4=IlEVSsz[%>| ԚJ7zjSO'D(/]:C@REkCqqd|_:42Qv |d'Cr|JiHe+K:|{}yqNh‘9ѫ?A=u7:tO%Etvk7ku²?SȄXuz&o9?Hpi38wgfExOnj>2t~ lnǒ{55t4X,EաHiaެ5}WV$G WYgcw)_r2-sX~X_4?^Y} Qg^%l|e0 Ҍ3D}% gU+Lwg<)*sC~܈ bU;4;~|`U֔K _L>|5Hm7 4<Ж |,ӏNYJZ@/lmdnKV34{_mQ 9%Ai!j!RNcHLۨjv_zNK˦VuOPS^]-JJWVS59?#O /69%Kms`8\`Ae>9"#/:n?Nvf:7:Xn@H.Sz+~ZwmD]_j6~1>9!2Ə <ɶFMY3]{\K3jw~777#Ve4GCi=gj#o'Z/edb}{?#O2#AEKZDҐfV[U73qb#xՋI ]V0wL[ <Ȫ=R7,1ST $ټ~} ٯN1>Ѳ۪= 3f /XO)D Kdz '<# rm6KPa_c$]n^i~ತU`5SO ߟy7n񵉖-o4O 䖨VzI]mնBW\O#&&8ݝt R"Tver?a{-]GmW_RYW*)V4Ө`?-q}8KXv/>DZO۟yK^lY N^*L}Y 6]`O̽#bmc#q)-{S+)QdXQTE{[_,ӵAY:M6937hsӫWw@Hg6V)Lt}m1;Mάy_eMYuq~[GrƇ[&_F!d/!Zl_l\y9EX#ixVOYYsqS;IE]Ym].˶mvl]e۶}盈;&F$gkeܸ`R:FqBx 7!p::G3S$k'>;b/w-?XBƀl4PM\X{#8y"d#q:\mnw83ivyWSX9C%#<^%!dBeBK )"uSFG43\QzIdOS,"\ue!4$ɸ1Qf|@ #eDK/RGܱ|2bG~ᆤpi@Hmnr?!++"F6N=`7ۡfHv@uoS"GZPZF) `HuW1#~s~Rs\p"!azA=Aij? :E hH(qlCVgeImpl/bߕ ?}"(%@F-r8ÿ b0A*p} Л؍⒓b^iur _)Dt+H]}Ao@LF[L] p1Rk4ͯ ýz^f7<'p Ҁ7aȿI;ד"v茎z3_L Ⰹ2@7b͒ >(?pղ\hޗ$%ڏ30llng@ʄ6ϨUeV\ b 8sr", [ Z*JvS~DVvF`,)™h94pQW?[]?]Q\Ҫ Sе,V5HsLJ;Q-mnQDS[ޔ̾iWtTsBFΡVg.mk⧰0?!S@hp;2e2i_QHUN9\tګ{Z=ԗ$0*u8 V`Leuig90//NиV̝iB;ւ֚CjUiPX1:ݛUIjjj-gbhs'LؑeJA稪d7D6W<Ө R@i?o_2IH`)J$* Q 11OvOE\6f x8wܫ]:Dˑ >=P6ЌEq*ʙlCV&˕%RDmC_RG;`6z^.e;?oV,5wܭaiE;aڷMxq lp13NۃFD 9|^1^62垨&L'(%*-Kۤ͗c؋&aL@¬7w~M (a*1C ܰI"MN7h>7LGL*`1V6B0Z1ɠ{aEf=EE0`Ss3Tl!U'BSa5},ֲu8n@P1z{^sn+䠊̇hJSKn ,)^ae>^2&7Ro{_.۽qCEL7be69uD%޻KSJݘL4>>o׿Z*[ID 򈂣) s*/Cr&N(qH8k+oTTIc>nv=؄ YZKrfX(_ u/6cә}эAPG#'q%|Y c}/J/xffר6Z k"ڽ;oTظ]IKO,Ќs\D(J͚Ǽa*XcDa:L䴊dN(3F)ID~Ez:Qmz\j(]bBS < dχL/#[W9wsZec]f  W4LTbVtQn5aK9#tԕЎjĀcr4_//]|kwգndJhd72ʵ 7Rehp"GU[Ct u)OU;ch<|܊lyȅPoJ3el &Z+|3U@K-:.zJZL`Nc*̦O1  ĸocd謩ɔ:fZ/-mrM'܋b!2 :|UA< @PXC(L_-]_&G;'ÑD%e!ZâIU8}'QPݽ|1]m?~s֎S>n4齌ž.#4mG6(miBu_LݻCxd>4; ϫ CZ|-C?0yA^-?'Lcsix;eδh;;Sauh\5EkaSlt l4br]'"b[ t6]49ym]& ȐX<L{Őۉf֨{Xt Jf])o⤁ 2lK2!V>̩\ V dN Z 55+dTiZ3c)3GJwym JPXDS^ cCFKC#__de`^±gf;OF4|ֿ6?k| 6(=9X|DH'Bs"cc쨍mO}!%vX@A(zIM 236Kum$A % "ZU}`84@Be91ux\, NwYjyf>bzfLvם~xvSE ɓDP\7'Ow=5wÁH}9hɝna}nQj>߻ ÑWW\A#߼?Q 3i--{Gpp MmmРC~*/5wzH+ z0ab${1EYO. .h\d2MjXʝ! oo9xʢqة66"G0 kl؇ǭTM$BX㦐s2YB]yk93#)&2x+ .6MD. ԙd|~?qu[T](ַLr G}fgER?~߻ aM~fHpTƜ/kK}Z MǺO Sx}NOєi׉9q]I[v-ym#a6#7**YKhZZ-~15,b(<~_IgذBx:;O_FSf_إ\ ?n@{gw9) ޔ*6'Pef›? 'L|f^,w {#'8 DzwT: fl}R(QOiXjʦ)&?OeQ0'20j4~9kuLljnM#gP+-ER.2M:do2č(Kۓ:?|'0Tߒf)Sn'X m7yy΂=9?BC_Td #<|np.!+\_e%~GFݤ5F<_x{ك {xrn#,Ep=$bo~8[ z5e>@2C;Ñm84lBgW%zZmQw~#f6< @= TyHub1&~Jdj5`Esǐ%@J wG&g/ceꏻ W?}]xS2F1u}  E@қAQ:Cq29&>)N}~3 zn~m\Qњ9D B}(`Z,y-BK=۽ )EFoƳ?ABPGP)WNLU F,ڰduf˵ !' yFM@KM(t,H]"ep >^c:jKv'+s8'AtÆGIUUk4vZ`K(p US ̱P [0D``ǣOcg!LFY:Ozd dy-\Ih`V&h? bɜɊ+ pfԼlrHj֋V*ψ;==kyԚW}Fp&Z51!cpC&X]edLSSqy_ԤL zABX1q姭mrr&l[Hdȅ#CZC+ ri'Iĕ^4)ZhܨjX:C0'~altHh 3Cc}"U &ܚLHxEl Eę"STtYZ2W=+q4 QP-ZtXvkMIˋl6<&xgM}kwkQMQA[A{S{ytaK?t> +r&}ablΡ0AX<@[S՞s(b&JMb Sw4SmQs4x ?H2=;pX~V$ĭíCPf_˽վ\ۨ <^ vCݱԯ^(8U)F΍Nvbјy;+Cs1F1ŕ@eC!H;'nelg^̀B%C}$ww kaFeZe:r;ۥ*,xk#;Qhi%qTCh0/a< *\|HK cH04zxa/E3`C[`tq"v>#;|(-%ʦ|=jS lv^p837 HqD Ҁx͹$v"4܌-e筳] Fu냯iXZ+*#NfzJI(g jH2x#5)1(4XǸ2:/̩T`!$|u-\]j> Us!9ˬʵ}}ؿXMG^#bo܊{)'8ކ~@Btv#rf mlTlqo"' alYDX\n6LƋ[t*NCۢ;3FM. X"T0`V}9DVr,IwQ'mvmP#6!%=zD埴3ydhW2}S"}tXoz҇3(o7qt7liwmUtf<tƳ#=+ -"! ) JJirTą㙾wR7 2tr#;#-$(LxR6jAToY6G ~y2#-(oGiP',adb3-mY\a9qr_a`y =+U\m]$,_"#.rq d4n28av_̄377B>aL@< (6~>Օ=rZ˃+Jnw- lVn3pXNaqe#agqGK'Hֶ\gjR==nbg5rNѾBUC+5LR cu( V.Fτ{gpTLp.CF[,3-ne`ꮰ_nd]Zk1mT3"`َvb(#!>Z 3sܼpPbz}z}dGޒP26hAڪt*瑮osFM'[y =QJSW6ݏKmjv/&C g`xGcۛy63WhUnB-P.s&]qL3^XtjUQpp0~J^}< ۪4RS)ɬѲD_*P$~ Gy69T0WN  ^ ' M^͟(o.[o\K1B-WSѱ+R[Okg_;C{x.@ XXj%jZټjEY=58(,}@ ؅KK;Ukpjy`IwTqt?&*X[_2lw&YQ;C/g > Dw d% fG88P^ٙg RVxM!  \Jik%4_4n觊iLs9]<9Du:Eqz.Tކ`3)P#i"+R*zZ3]1Q0kl-V[ޞJ11kl:*{U$ǷVUW |ޮyl ]M&+%Lˤk+ ;l sUCM#$ݏYnmrq.ׯThk7?َHgel@ 6WKzMlz_q'"vs8Ňԅhk]ߔ>ohf?d`@ELOCk9ܞi^)V"2م}i"7SZ3`O\'zzJ6b#d6>L+Ͱ+#15fFzFկTonjck#҃qE0(V`<͟SOŽg17rqc%ų[ |@ ̦z'<#ǗŐb6?4&utURٰ(5jꯑ4W?ϪĆl 4:îTJ^_ b>+rA@ːг]H_'g-Cdh|/]@R-3O8YHbԋATKkx9oф#btHA~^;n|F=r?Nit_/}F)j2D]9zh1s?i|yLlfBp0GkՓPiS^ oa~\8W7[O^Io@]_ۺǛOC}Lξfnz|?~L7 ?۔6yE>`ݻ;X=]ޮO{wo3PJ)M^_P,OL}c~2ɹFAL'ҢO$BL./ j棵,?7CyC-c-cIՁ~fh)) ^q$hKnah<%:zGm͘4:2Ws sQȼ'm/u^o}w_/惢UO,f3U2=0 ;Wtnx,\:422Z쇸 xģܑjjmNpV<_[pO3`gCEެok}1#= ,9'DD|X!H1hnif 2ɭM0wǯN>L4_5mu:!<1?&,$,*%%*|ʼnk^.%H+PJ-0lQ#bN瑩q +Pr*yJXP`ZZA[Wòٓr9Ji)Iv?KOڔRM8P$vRO3xp;,wZ ӥ0QsaQ MYy'ۻh3k 3_Z*V=h.P '=w&}OE#L$:)avM>BVC,0}ui`5}_~<쩄Ln訽'3I) 4 `Zvm%j2ᄈ( *ܯ;뉜)h?1\dTiÊ[FnǪf܉G88jND󼎫ex10 vJ_71Dwb[>Ĉ%SZsZQZ*0h5yÓx o7&DՖ.0iQ,6 -|Y)/ស^=աz EP/Y<٫aNU|)mUe (u`ɱtR9nM|̊K`kemg6Qn9?2O_WGṽw3`S-Y 3l"s236EeK0,qjjDH㙿S6aHfHV¼b#dE0_1(d\q_Q= i MJgZ+U_9ns Х/>;8n*j/N= 7Ub=¸r0&}+@rgM4׶< `K(iA-!Z &a<46%FO:b Mfzwdw#a>riҳ\x١m4rp}Ļ,o~c`ZTܳF<~"0N^&ak͵aw9$v0 3yj`i j4J#Ĉa۾Ѓ6@5uΓ囸R}/M ݫ0m༊L|ɗLK7KPD3_$r Ӷ5{ xauPkA2% Oְ|yǧ+lg rKc^8桦+v>&Q!"i;o;=Uȩ1o;Iu5 ~ݛ`MEl_Y49%C $;;1bFX}Y=tJdwaW @,w=_uiM:[bZy']-/7\dZ~Q֦er-O j4+r9{oFc2Ii4hY۟Lg \j͝Wj&,M Ú32ֈe5|u 'DjdOQKk"Ohjbly)>llh*,xUT |o,WșJ[lh*P>C): &*Tɹr1w"0*x3R`OMPZ' [\GPNJ%]ߔ%(iɃ;L$Ǧ沕iAr7s݄`ć1w8x.˖a?EV[Qx-n/<;LdE _l x߇}Ny1ʬ9a"bxQyzNޛ|w#|E`/zʉi1AJ0@8Mr$>罅q5 Dx!eӢH%%쪊̗*Wk"Ci^\T7(A'٭l>5 $`ɔD+ cT!A]gT{TM8:SNum-{ _ %)7JF '[VyzX1FC #y#G G*/caURܫmT*kӃIWoc^יy|d~'s+Gӛm9,d^Q?[\ l)%8@5ļ|.>I*N^AdUu!A LO~/pC5@&G ik<3g$]LV|ݨ{F}mb~Y0h%Ȅ+|Em>P0Y%3r}±2P&Kmq*➬u .\Oud&6"/|HBǬgQDXeA^"^sh΃jN'NW+/6ۯϙ n@ejTN|TC/a; sͫua?0@8oCn"Z``fBۋu"7J-/BBhjtoql7S>J6!nYUͤʦ P z a:.Yϔ@6oXѓlf9i,2[5=goz.rIaV}JLv`{Edh„0$݃TPfMjĭCʓ& ZL(џ_ZvהmwuOr?V pBoo@ˎ '*؈#*DT кH fՅ;yd[qɣ3[=,x-9`ܪn6P,X5DaraK (A֙a&ʗ6I&(X3SAiRY F6z|0UD]Q=)[Ptй,veiQࡾÈFH1"ݏ?(U`We3ŝw< i@{J_"~J ,cvS"ū1B h EYq]%Qxbyx /\:4iV<$*B 6lqZU,*dĀrR0Ezva+|߅VcknL| A}wE@#&@BI@_qVzNZ3%Q+;e5i|sjZf%Rv_ ܬwЀk˵a_!>\WPSg+BwHs~jn \E ܱ64·CCS_x%ar$b]x1vG=ZV|Q_D 9s3˪&ٵy];([QKG==YF *0@gg0ir@8^`Eじ*zqfbciebNw'~Q{cOްh& ,}]t_+?~ wO7ϺȂ;? "6·L5,xh7;D=o1#r&Oi?~+u/\ O~!| ky>wsgKP1NЊU"GDь򸞨Fj\ E Aqn:#bhH>m.)kgTMz& B -ZB:09ДN1n֌]o-P:Yܣ 6L^v#Hv߹EDj Kakĵ,7oX^B_FY﷠ҍhX0#8G]> Nj @H4~᧹xGk\'0 Њ .lul) %G%ƖtaU0ړUg=_K'm|evbetS"ChbSyuڄ꛳Af(@ţV'xW$\-v6Ow,V^I8`,[LGu|K=xOw9VS-W W[5[Ґ|%$RxijpcKۈi^FKC|ǹejīW'O4#?h} #A{Dr8/iZ4M-m՗ F?a1[ȅࠆ@z "~BXWDyϮr 9?C8Q rT03k63A CF 0RIL-p';N9~>qQm%(    "PowerPoint.Show.Oh+'0T hp   $ 0<DIssues Facing PBMsTerry LatanichBmh_template_white!Merck-Medco Managed Care, L.L.C.Mi35cMicrosoft PowerPointare@v9@3@'}GSg  )'    """)))UUUMMMBBB999|PP3f333f3333f3ffffff3f̙3ff333f333333333f33333333f33f3ff3f3f3f3333f33̙33333f333333f3333f3ffffff3f33ff3f3f3f3fff3ffffffffff3ffff̙fff3fffff3fff333f3f3ff3ff33f̙̙3̙ff̙̙̙3f̙3f333f3333f3ffffff3f̙3f3f3f333f3333f3ffffff3f̙3f3ffffffffff!___www4'A x(xKʦ """)))UUUMMMBBB999|PP3f3333f333ff3fffff3f3f̙f3333f3333333333f3333333f3f33ff3f3f3f3333f3333333f3̙33333f333ff3ffffff3f33f3ff3f3f3ffff3fffffffff3fffffff3f̙ffff3ff333f3ff33fff33f3ff̙3f3f3333f333ff3fffff̙̙3̙f̙̙̙3f̙3f3f3333f333ff3fffff3f3f̙3ffffffffff!___wwwýýཽüýýཽښà½ýš½üÚýýü½üýýོ¼¼¼¼ý½ý ýý½ݼ½ݼ¼½ýÚ½ý àÚýýýàü⼻½⼼½¼üÚýýýxݘ»¼ý š½ ޚýýýýý¼ü¼àuzy½ýàš½½zYSWrÚ ½ýýzYzyPàýýýuYzIrýýýšüÚYYzyPrý½½ýýzuuYtýýÚ½Úyzýýý½½ýà Úýý ý½CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC½ýýཽýCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCý½ àýCCCCCCCCCCCCýý ü ý ½ý½ýýýýýÚý½CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC ½½àCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCýÚý CCCCCCCCCCCCCý½ýü½ýýÚýàCýýš½ýýCCCCCCCCCCCCCCCCCCC½ýýÚàCCCCCCCCCCCCCCCCCCCCCÚ àýýCCCCCCCàýý  üààý ýüýý½Úšààà½ýýýàÚ½ý ý½ ½CCÚ½½ýCCCCCCCCCCCCCCCCCCCCCCCCCCCCýàý½à CCCCCCCCCCCCCCCCCCCCCCCCC½ýý½CCCCCCCCCCCCCCCCCCCCCCCCC½ýüýà½CCCCCCCCCCCCCCCCCCýàýýÚ  Ú½CCC½ ýCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC½ýÚ½CCCCCCCCCCCCCCCCCCCCCCCCCCÚ½½½CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCýüàÚCCCCCCCCC½Úý½ àüàý CCýýýCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCüýýýCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCý ýÚ½ýýCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCýýý ½CCCCCCCCCCCCCCCCC à  ýàýàýàÚ ýýýà½ýýüàýý Úýý Úš½ýýýýý½ ýýàýཚýýýýà''''ýýý½à½''Úàý½à''''''''''''''½ýš''''''''''''ýàý š''''''''''''''ýýý'''''''''''''½ýý'''''''''''''''''''''àý ý¼ý''''üý½ý ýšÚýý½ý½½'''''½½ààÚ'''ý½š''''''''''''''''''''''''''''''''''''''''''''''šý½ýÚ ''''''''''''''''''''''''''''''''''''''''½ýššý''''''''''''''''''''''''''''''''''''''''''''½½''''''''''''''''''''''''''''''''''''''''''ý ýš'''''''''''''''''''''''''''''''''''''''''''''''''''''''ýšš½'''''''''''''''''ý½ý½Ú'Úࠚ¼'½ýššÚ½'à½ýÚü''''''''''''''''''''''''''''''''''''''''''''''''½ý½½š''''''''''''''''''''''''''''''''''''''''''''½üཽ'''''''''''''''''''''''''''''''''''''''''''''''''''''ýý''''''''''''''''''''''''''''''''''''''''''''''''''''ýýà½''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''üš ''''''''''''''''''''''''''''''''à½'''½Úššš½šsssssssssss½ý½ý š½Ú½ý àÚýýýšÚýýýý š½šýýýýš½ýàš½Ú ½½šàý½ýýýš¼ý½½½ýýÚ½ýýý¼ý Úýý ý½½ýýཽýý½ àýýý ü ý ½ý½ýýýýýÚý½ ½½àýÚý :A 0 DWingdingsRoman0:A 00DSymbolgsRoman0:A 0 B0.  @n?" dd@  @@`` T9    /Xb$ZBW,e6Vxb$h$>RU-U# lAA1?@8ʚ;ʚ;g44d4d :A 0ppp@ <4ddddL$ 04 <4BdBdL # 0A9___PPT10 6?  O  =lCWill PBMs Participate in the New Medicare Prescription Drug ProgramDD$;The National Medicare Prescription Drug Conference February 27, 2004 Terry S. Latanich Government Affairs Consultant Medco Health Solutions 4PFFPotential Roles for PBMs $ 2004 Discount Card Sponsor drug discount card plans Provide  Intel-side for M+C discount cards 2006 Funded Benefit (Direct Participation) Serve as PDPs Serve as PDPs with dialed-down risk Serve as federal fall-back plansPN+SN+S Potential Roles for PBMs $ 2006 Funded Benefit (Indirect participation) Provide PBM services to traditional risk bearing organizations, e.g., insurers, health plans which choose to become: PDPs Regional PPOs Support employer-sponsored plans B"  !Key Capabilities Provided by PBMs"" Develop pharmacy networks Implement POS technology and DUR programs for seniors Track patterns of prescribing by physicians and patterns of usage by seniors to improve care Facilitate e-prescribing to improve patient care and outcomes !Key Capabilities Provided by PBMs"" Specific obligations under HR 1 Develop medication therapy management programs Long sought by pharmacy Source of reimbursement has been hurdle Negotiate rebates and price concessions with drug manufacturers XOP@PAPPO@ADiscount Card Program 3Only deliverable prior to 2004 elections New business opportunity for PBMs which have historically been focused on selling to health plans, not in the direct to consumer market Financial Investment Required Cost of initial enrollment versus ongoing operations Build brand identification before 2006 benefit NS/S/ Discount Card ^CMS regulations recognize that $30 enrollment fee will not cover the costs of enrollment and ongoing operations Expectation has been created that manufacturers will participate in funding savings, not just pharmacy Manufacturers must offer significant discounts and rebates to make the card successful Controlling Drug Prices Price versus utilization as cost-driver Formulary categories delegated to USP Medical Necessity Overrides Plans can establish objective criteria for approval Must be specific to a beneficiary, not physician preference E-prescribing as formulary tool LjZpZ"ZZjp# PBMs role in 2006 Benefit QRisk is mitigated in the early years, but still remains high PBMs have not assumed insurance risk No reliable utilization history in early years PBMs have an after-tax profit of 1-2% per SEC filings PBMs will review current business model How many PDPs emerge in early years Will PDPs enter if dialed down risk or fall-back implemented BcPPc  !PBMs as Fall-Back Administrators "  ?Cannot be a PDP or subcontractor in any plan nationwide and still seek fall-back provider status May not establish brand identity Not a traditional role for PBMs Support current clients or move closer to an fiscal intermediary model Government role in developing formularies and negotiating prices in the fall-back plan  Conclusions   BFirst litmus test for success will be the discount card program; early indications are high level of interest Whether M+C, new regional PPOs, employer-based programs become widespread offerors or free-standing PDPs or reduced risk PDPs become the most prevalent offerings, PBMs will be key to the success of the program 2AA-K0  $(  r  S XE@p.  r  S ,F@0P  H  0޽h ? 33___PPT10i. +D=' = @B +r[m7 (    "PowerPoint.S      !"#$  !"#$%&'()*+,-./0123456789;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root EntrydO)P7)'}PicturesIsCurrent UserSummaryInformation($UPowerPoint Document(:9lDocumentSummaryInformation880BMicrosoft PowerPoint Presentation/ 00DArialgs40:A 0DTimes New Roman0:A 0 DWingdingsRoman0:A 00DSymbolgsRoman0:A 0 B0.  @n?" dd@  @@`` T9    /Xb$ZBW,e6Vxb$h$>RU-U# lAA1?@8ʚ;ʚ;g44d4d :A 0ppp@ <4ddddL$ 04 <4BdBdL # 0A9___PPT10 6?  O  =q6Will PBMs Participate in the New Medicare Drug Benefit77$, The National Medicare Prescription Drug Conference February 27, 2004 Terry S. Latanich Government Affairs Consultant Medco Health Solutions 4PFFPotential Roles for PBMs $ 2004 Discount Card Sponsor drug discount card plans Provide  Intel-side for M+C discount cards 2006 Funded Benefit (Direct Participation) Serve as PDPs Serve as PDPs with dialed-down risk Serve as federal fall-back plansPN+SN+S Potential Roles for PBMs $ 2006 Funded Benefit (Indirect participation) Provide PBM services to traditional risk bearing organizations, e.g., insurers, health plans which choose to become: PDPs Regional PPOs Support employer-sponsored plans B"  !Key Capabilities Provided by PBMs"" Develop pharmacy networks Implement POS technology and DUR programs for seniors Track patterns of prescribing by physicians and patterns of usage by seniors to improve care Facilitate e-prescribing to improve patient care and outcomes !Key Capabilities Provided by PBMs"" Specific obligations under HR 1 Develop medication therapy management programs Long sought by pharmacy Source of reimbursement has been hurdle Negotiate rebates and price concessions with drug manufacturers XOP@PAPPO@ADiscount Card Program 3Only deliverable prior to 2004 elections New business opportunity for PBMs which have historically been focused on selling to health plans, not in the direct to consumer market Financial Investment Required Cost of initial enrollment versus ongoing operations Build brand identification before 2006 benefit NS/S/ Discount Card ^CMS regulations recognize that $30 enrollment fee will not cover the costs of enrollment and ongoing operations Expectation has been created that manufacturers will participate in funding savings, not just pharmacy Manufacturers must offer significant discounts and rebates to make the card successful Controlling Drug Prices Price versus utilization as cost-driver Formulary categories delegated to USP Medical Necessity Overrides Plans can establish objective criteria for approval Must be specific to a beneficiary, not physician preference E-prescribing as formulary tool LjZpZ"ZZjp# PBMs role in 2006 Benefit QRisk is mitigated in the early years, but still remains high PBMs have not assumed insurance risk No reliable utilization history in early years PBMs have an after-tax profit of 1-2% per SEC filings PBMs will review current business model How many PDPs emerge in early years Will PDPs enter if dialed down risk or fall-back implemented BcPPc  !PBMs as Fall-Back Administrators "  ?Cannot be a PDP or subcontractor in any plan nationwide and still seek fall-back provider status May not establish brand identity Not a traditional role for PBMs Support current clients or move closer to an fiscal intermediary model Government role in developing formularies and negotiating prices in the fall-back plan  Conclusions   BFirst litmus test for success will be the discount card program; early indications are high level of interest Whether M+C, new regional PPOs, employer-based programs become widespread offerors or free-standing PDPs or reduced risk PDPs become the most prevalent offerings, PBMs will be key to the success of the program 2AA-K0  $(  r  S XE@.  r  S ,F@0P  H  0޽h ? 33___PPT10i. +D=' = @B +rUm1 (    "PowerPoint.Show.80BMicrosoft PowerPoint Presentation/ 00DArialgs40:A 0DTimes New Roman0 ՜.+,D՜.+,x    On-screen ShowParagod9lC { ArialTimes New Roman WingdingsSymbol chelseapier"Microsoft PowerPoint PresentationDWill PBMs Participate in the New Medicare Prescription Drug ProgramPotential Roles for PBMsPotential Roles for PBMs"Key Capabilities Provided by PBMs"Key Capabilities Provided by PBMsDiscount Card ProgramDiscount CardControlling Drug PricesPBMs role in 2006 Benefit"PBMs as Fall-Back Administrators Conclusions  Fonts UsedDesign TemplateEmbedded OLE Servers Slide Titles 8@,_AdHocReviewCycleID_EmailSubject _AuthorEmail_AuthorEmailDisplayName_ReviewingToolsShownOnce&FW: ewiterry_latanich@medcohealth.comdLatanich, Terryata8_l Merck-Medco Managed Care, L.L.C.Merck-Medco Managed Care, L.L.C.how.80BMicrosoft PowerPoint Presentation/ 00DArialgs40:A 0DTimes New Roman0:A 0 DWingdingsRoman0:A 00DSymbolgsRoman0:A 0 B0.  @n?" dd@  @@`` T9    /Xb$ZBW,e6Vxb$h$>RU-U# lAA1?@8ʚ;ʚ;g44d4d :A 0ppp@ <4ddddL$ 04 <4BdBdL # 0A9___PPT10 6?  O  =JCWill PBMs Participate in the New Medicare Prescription Drug ProgramDD$The National Medicare Prescription Drug Conference February 27, 2004 Terry S. Latanich Government Affairs Consultant Medco Health Solutions 4PFFPotential Roles for PBMs $ 2004 Discount Card Sponsor drug discount card plans Provide  Intel-side for M+C discount cards 2006 Funded Benefit (Direct Participation) Serve as PDPs Serve as PDPs with dialed-down risk Serve as federal fall-back plansPN+SN+S Potential Roles for PBMs $ 2006 Funded Benefit (Indirect participation) Provide PBM services to traditional risk bearing organizations, e.g., insurers, health plans which choose to become: PDPs Regional PPOs Support employer-sponsored plans B"  !Key Capabilities Provided by PBMs"" Develop pharmacy networks Implement POS technology and DUR programs for seniors Track patterns of prescribing by physicians and patterns of usage by seniors to improve care Facilitate e-prescribing to improve patient care and outcomes !Key Capabilities Provided by PBMs"" Specific obligations under HR 1 Develop medication therapy management programs Long sought by pharmacy Source of reimbursement has been hurdle Negotiate rebates and price concessions with drug manufacturers XOP@PAPPO@ADiscount Card Program 3Only deliverable prior to 2004 elections New business opportunity for PBMs which have historically been focused on selling to health plans, not in the direct to consumer market Financial Investment Required Cost of initial enrollment versus ongoing operations Build brand identification before 2006 benefit NS/S/ Discount Card ^CMS regulations recognize that $30 enrollment fee will not cover the costs of enrollment and ongoing operations Expectation has been created that manufacturers will participate in funding savings, not just pharmacy Manufacturers must offer significant discounts and rebates to make the card successful Controlling Drug Prices Price versus utilization as cost-driver Formulary categories delegated to USP Medical Necessity Overrides Plans can establish objective criteria for approval Must be specific to a beneficiary, not physician preference E-prescribing as formulary tool LjZpZ"ZZjp# PBMs role in 2006 Benefit QRisk is mitigated in the early years, but still remains high PBMs have not assumed insurance risk No reliable utilization history in early years PBMs have an after-tax profit of 1-2% per SEC filings PBMs will review current business model How many PDPs emerge in early years Will PDPs enter if dialed down risk or fall-back implemented BcPPc  !PBMs as Fall-Back Administrators "  ?Cannot be a PDP or subcontractor in any plan nationwide and still seek fall-back provider status May not establish brand identity Not a traditional role for PBMs Support current clients or move closer to an fiscal intermediary model Government role in developing formularies and negotiating prices in the fall-back plan  Conclusions   BFirst litmus test for success will be the discount card program; early indications are high level of interest Whether M+C, new regional PPOs, employer-based programs become widespread offerors or free-standing PDPs or reduced risk PDPs become the most prevalent offerings, PBMs will be key to the success of the program 2AA-K0  $(  r  S XE@p.  r  S ,F@0P  H  0޽h ? 33___PPT10i. +D=' = @B + -K0 0 0(   x  c $<o>f   x  c $h<o   H  0޽h ? 33___PPT10i.PA+D=' = @B + -K0 0P<(  P~ P s *<o>f   ~ P s *P<o   H P 0޽h ? 33___PPT10i.PA+D=' = @B + -K0 H<(  H~ H s *\<o>f   ~ H s *0<o   H H 0޽h ? 33___PPT10i.PA+D=' = @B + -K0 @T<(  T~ T s *е<o>f   ~ T s *<o   H T 0޽h ? 33___PPT10i.PA+D=' = @B + -K0 @<(  ~  s *Þ<o>f   ~  s *Ğ<`?   H  0޽h ? 33___PPT10i.PA+D=' = @B + -K0 $<(  $~ $ s *<o>f   ~ $ s *`<   H $ 0޽h ? 33___PPT10i.PA+D=' = @B + -K0 (<(  (~ ( s *|<o>f   ~ ( s *< `o-   H ( 0޽h ? 33___PPT10i.PA+D=' = @B + -K0  L<(  L~ L s *L<`/x   ~ L s * < `o-   H L 0޽h ? 33___PPT10i.PA+D=' = @B +r8\0b79D |G1J@]?L<Bm8O(    "PowerPoint.Show.80BMicrosoft PowerPoint Presentation/ 00DArialgs40:A 0DTimes New Roman0:A 0 DWingdingsRoman0:A 00DSymbolgsRoman0:A 0 B0.  @n?" dd@  @@`` T9    /Xb$ZBW,e6Vxb$h$>RU-U# lAA1?@8ʚ;ʚ;g44d4d :A 0ppp@ <4ddddL$ 04 <4BdBdL # 0A9___PPT10 6?  O  =JCWill PBMs Participate in the New Medicare Prescription Drug ProgramDD$The National Medicare Prescription Drug Conference February 27, 2004 Terry S. Latanich Government Affairs Consultant Medco Health Solutions 4PFFPotential Roles for PBMs $ 2004 Discount Card Sponsor drug discount card plans Provide  Intel-side for M+C discount cards 2006 Funded Benefit (Direct Participation) Serve as PDPs Serve as PDPs with dialed-down risk Serve as federal fall-back plansPN+SN+S Potential Roles for PBMs $ 2006 Funded Benefit (Indirect participation) Provide PBM services to traditional risk bearing organizations, e.g., insurers, health plans which choose to become: PDPs Regional PPOs Support employer-sponsored plans B"  !Key Capabilities Provided by PBMs"" Develop pharmacy networks Implement POS technology and DUR programs for seniors Track patterns of prescribing by physicians and patterns of usage by seniors to improve care Facilitate e-prescribing to improve patient care and outcomes !Key Capabilities Provided by PBMs"" Specific obligations under HR 1 Develop medication therapy management programs Long sought by pharmacy Source of reimbursement has been hurdle Negotiate rebates and price concessions with drug manufacturers XOP@PAPPO@ADiscount Card Program 3Only deliverable prior to 2004 elections New business opportunity for PBMs which have historically been focused on selling to health plans, not in the direct to consumer market Financial Investment Required Cost of initial enrollment versus ongoing operations Build brand identification before 2006 benefit NS/S/ Discount Card ^CMS regulations recognize that $30 enrollment fee will not cover the costs of enrollment and ongoing operations Expectation has been created that manufacturers will participate in funding savings, not just pharmacy Manufacturers must offer significant discounts and rebates to make the card successful Controlling Drug Prices Price versus utilization as cost-driver Formulary categories delegated to USP Medical Necessity Overrides Plans can establish objective criteria for approval Must be specific to a beneficiary, not physician preference E-prescribing as formulary tool LjZpZ"ZZjp# PBMs role in 2006 Benefit QRisk is mitigated in the early years, but still remains high PBMs have not assumed insurance risk No reliable utilization history in early years PBMs have an after-tax profit of 1-2% per SEC filings PBMs will review current business model How many PDPs emerge in early years Will PDPs enter if dialed down risk or fall-back implemented BcPPc  !PBMs as Fall-Back Administrators "  ?Cannot be a PDP or subcontractor in any plan nationwide and still seek fall-back provider status May not establish brand identity Not a traditional role for PBMs Support current clients or move closer to an fiscal intermediary model Government role in developing formularies and negotiating prices in the fall-back plan  Conclusions   BFirst litmus test for success will be the discount card program; early indications are high level of interest Whether M+C, new regional PPOs, employer-based programs become widespread offerors or free-standing PDPs or reduced risk PDPs become the most prevalent offerings, PBMs will be key to the success of the program 2AArOmOlRoot EntrydO)Q}+@PicturesIsCurrent UserSummaryInformation($U      !"#$*,-) Beverly (FLKS)&t:""; margin:0in; PowerPoint Document(:9lDocumentSummaryInformation8՜.+,D՜.+,x    On-screen ShowParagod9lC { ArialTimes New Roman WingdingsSymbol chelseapier"Microsoft PowerPoint PresentationDWill PBMs Participate in the New Medicare Prescription Drug ProgramPotential Roles for PBMsPotential Roles for PBMs"Key Capabilities Provided by PBMs"Key Capabilities Provided by PBMsDiscount Card ProgramDiscount CardControlling Drug PricesPBMs role in 2006 Benefit"PBMs as Fall-Back Administrators Conclusions  Fonts UsedDesign TemplateEmbedded OLE Servers Slide Titles @\_AdHocReviewCycleID_EmailSubject _AuthorEmail_AuthorEmailDisplayName_ReviewingToolsShownOnce_PreviousAdHocReviewCycleID"x*Terry Latanich - Power Point P8_l Merck-Medco Managed Care, L.L.C.Merck-Medco Managed Care, L.L.C.resentation!beverly_sullivan@medcohealth.comSullivan,